* Despite the ability of #GLP-1s to produce significant #weightreduction and related health benefits, challenges such as GI side effects, risk of nutrient inadequacies, #loss of #muscle and #bone mass, high costs, frequent discontinuation, and #weightregain limit the use of these drugs for #longterm #success in individuals and populations
A newer GLP-1 receptor agonist, tirzepatide, demonstrates weight loss as high as 20% change in body weight compared with 3% in the placebo group in a RCT
If the goal is creating pressure or encouraging unsafe behavior, the number should be revisited with support rather than treated as fixed
Work With LumaLex Law If your company sells peptides, research chemicals, or wellness compounds, you should reassess your GLP-1 exposure now
In addition to quieting that food noise, these types of weight loss medications can actually reduce heart disease, "that might be independent of weight loss," in addition to "improvements in heart function and functional status in individuals with heart failure." The medication is also currently being studied for how it can target symptoms of kidney disease and Alzheimer's
